胃癌靶向治疗的研究现状与进展

被引：27

作者：

冯睿 ^{[1
]}

张小田 ^{[2
]}

杨升 ^{[1
]}

机构：

[1] 福建医科大学协和临床医学院肿瘤学教研室

[2] 北京大学肿瘤医院消化肿瘤内科

来源：

中华胃肠外科杂志 | 2016年 / 10期

关键词：

胃肿瘤; 分子靶向治疗; 曲妥珠单抗; 雷莫芦单抗; 阿帕替尼;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100214 ;

摘要：

随着对胃癌增殖生长与侵袭转移等恶性生物学行为机制研究深入,靶向治疗已成为胃癌领域研究热点。目前靶向药物研究的热门信号通路包括人类表皮生长因子受体(HER)家族信号通路、血管内皮生长因子(VEGF)信号通路、磷脂酰肌醇3激酶-蛋白激酶/哺乳动物雷帕霉素靶蛋白(PI3K/mTOR)信号通路和NF-KB信号通路等。HER家族信号通路相关靶向药物,包括针对HER-1的西妥昔单抗、尼妥珠单抗、马妥珠单抗、帕尼单抗和厄洛替尼,针对HER-2的曲妥珠单抗、帕妥珠单抗和T-DM1,以及针对HER家族多靶点的拉帕替尼和阿法替尼。VEGF信号通路相关靶向药物包括针对VEGF的贝伐珠单抗,抗VEGFR的雷莫芦单抗、阿帕替尼、索拉非尼、舒尼替尼及西地尼布,以及重组融合蛋白阿柏西普。此外,在胃癌治疗中具有潜力的PI3K/mTOR信号通路相关靶向药物包括LY294002、BEZ235和依维莫司,而硼替佐米为现有研究较多抑制NF-κB信号通路靶向药物。目前胃癌分子靶向治疗领域完成的Ⅲ期药物临床试验且成功的分子靶向药物主要有曲妥珠单抗、雷莫芦单抗及阿帕替尼。未来研究方向应关注针对多靶点的药物或应用针对不同靶点的药物联合治疗胃癌。本文收集国内外近期相关研究和临床试验报道,对胃癌靶向治疗的现状和进展做简要综述。

引用

页码：1191 / 1196

页数：6

共 21 条

[1] 重组人血管内皮抑素联合多西他赛、铂类和氟尿嘧啶类一线治疗进展期胃癌的临床观察 [J].

杜春霞 ;

陈闪闪 ;

刘潇衍 ;

张弘纲 .

临床肿瘤学杂志, 2014, 19 (10) :925-928

[2]

Fibroblast Growth Factor （FGF） Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors[J] . Cinta Hierro,Jordi Rodon,Josep Tabernero.Seminars in Oncology . 2015 (6)

[3]

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer[J] . Bang Yung-Jue,Im Seock-Ah,Lee Keun-Wook,Cho Jae Yong,Song Eun-Kee,Lee Kyung Hee,Kim Yeul Hong,Park Joon Oh,Chun Hoo Geun,Zang Dae Young,Fielding Anitra,Rowbottom Jacqui,Hodgson Darren,O’Connor Mark J.,Yin Xiaolu,Kim Woo Ho.Journal of Clinical Oncology . 2015 (33)

[4]

S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial[J] . Feng Du,Zhaoxu Zheng,SuSheng Shi,Zhichao Jiang,Tao Qu,Xinhua Yuan,Yongkun Sun,Yan Song,Lin Yang,Jiuda Zhao,Jinwan Wang,Yihebali Chi.Medicine . 2015 (23)

[5]

Global cancer statistics, 2012[J] . Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet‐Tieulent,Ahmedin Jemal.CA: A Cancer Journal for Clinicians . 2015 (2)

[6]

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma （RAINBOW）: a double-blind, randomised phase 3 trial[J] . Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,Gy?rgy Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D Sch

[7]

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J] . Timothy Iveson,Ross C Donehower,Irina Davidenko,Sergey Tjulandin,Andrzej Deptala,Mark Harrison,Somanath Nirni,Kuntegowdanahalli Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S Oliner,Elwyn Loh.Lancet Oncol

[8]

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma （REGARD）: an international, randomised, multicentre, placebo-controlled, phase 3 trial[J] . Charles S Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,Giuseppe Aprile,David R Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Raymond Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori K

[9] A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer [J].

Kang, Yoon-Koo ;

Muro, Kei ;

Ryu, Min-Hee ;

Yasui, Hirofumi ;

Nishina, Tomohiro ;

Ryoo, Baek-Yeol ;

Kamiya, Yukimasa ;

Akinaga, Shiro ;

Boku, Narikazu .

INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) :355-361

[10]

Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis[J] . Ya-nan Ji,Qin Wang,Yang Li,Zhi Wang.Tumor Biology . 2014 (3)

← 1 2 3 →